A Phase 3, Multicenter, Randomized, Double-Blind, 24-Week Study of the Clinical and Antiviral Effect of S-217622 Compared With Placebo in Non-Hospitalized Participants With COVID-19
Latest Information Update: 17 Jun 2025
At a glance
- Drugs Ensitrelvir (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Acronyms ACTIV-2d; SCORPIO-HR
- Sponsors Shionogi
Most Recent Events
- 29 Oct 2024 According to a Shionogi media release, the data from this study were published in JAMA Network Open.
- 23 Jul 2024 According to an AIDS Clinical Trials Group media release, the results form this trial will be presented at the AIDS 2024.
- 04 Jun 2024 Status changed from active, no longer recruiting to completed.